GENE ONLINE|News &
Opinion
Blog

Singapore HSA approves phase I/II clinical trial for precision T-cell receptor immunotherapy

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K Gopinath

By welcoming its first ever TCR engineered T-cell therapy for liver cancer, Singapore has made history in August. The Health Sciences Authority (HSA) of Singapore approved the phase I/II multicenter clinical study for LioCyxTM, a personalized Hepatitis B Virus (HBV) specific T-cell receptor (TCR) immunotherapy against Hepatocellular carcinoma (HCC). Multiple trials have shown promising results in terms of its safety and efficacy.

Developed by Lion TCR, a Singapore-based clinical stage biotech company, LioCyxTM is the product of its scientific founder Prof. Antonio Bertoletti, a world-famous liver cancer clinician scientist. Lion TCR has licensed its engineered T cell technologies from Agency for Science, Technology and Research (A*STAR), Singapore and Technical University of Munich. The TCR-T and CAR-T cell therapies were developed by Prof. Antonio Bertoletti’s and Prof. Urlike Protzer’s labs respectively. The company now has the distinction of developing the first HBV-specific TCR T-cell therapy against HCC in the world. It has manufacturing and clinical trial operations in China and Singapore. It recently raised 20 million US dollars to advance the clinical trials of LioCyx™ and is currently all set to begin patient recruitment at the National University Hospital (NUH) of Singapore.

This is a significant milestone in precision oncology as Liver cancer is the third deadliest cancer in the world with limited treatment options. Post-liver transplantation, there is currently no effective treatment available for patient’s suffering from relapsed liver cancer. Hepatitis B virus (HBV)-related liver cancer, constitutes around 80 percent of liver cancers in Asia and a majority of the 800,000 new cases in the world are diagnosed in the Asia Pacific regions such as China, Vietnam, Thailand, Indonesia, South Korea and Singapore.

References

1. https://markets.businessinsider.com/news/stocks/singapore-s-first-clinical-trial-approval-for-t-cell-engineered-tcr-immunotherapy-for-treatment-of-liver-cancer-1027468832

2. https://www.epmmagazine.com/news/study-for-precision-tcr-immunotherapy-approved-singapore/

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION’S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
2023-07-28
M&A
AstraZeneca Expands Oncology Portfolio with $320 Million Neogene Acquisition
2022-11-29
AstraZeneca’s Liver Cancer Treatment Combination Snatches FDA Approval
2022-10-24
LATEST
Monash University Study Links Estrogen to Cardiovascular Protection in Women with Hypertension
2025-07-10
FDA Approves Ekterly as First Oral On-Demand Treatment for Acute Hereditary Angioedema Attacks
2025-07-10
Repeal of ACA Individual Mandate Penalty in 2019 Linked to Projected Rise in Uninsured Americans
2025-07-10
Expert Panel Highlights Role of AI-Driven Insights and Economic Incentives in Integrating Real-World Evidence for Payer Decisions
2025-07-10
Study Explores Impact of Nighttime Pistachio Consumption on Gut Microbiome in Adults with Prediabetes
2025-07-10
Asymmetrical Onset of Parkinson’s Disease Linked to Motor and Non-Motor Symptom Progression
2025-07-10
FDA Faces Challenges with Declining Experienced Staff and Low Employee Morale Amid U.S.-Swiss Pharmaceutical Trade Agreement
2025-07-10
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top